Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

BMS would make payments with respect to the CVRs only if the Food and Drug Administration’s approval of certain Celgene products was received by a specified date. Ultimately, the approval was received ...

26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric disorder. Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug ...

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, myasthenia gravis and other conditions traced to misdirected immune response.

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics ...

Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic ...